Actemra FDA Approval History
Last updated by Judith Stewart, BPharm on Dec 27, 2022.
FDA Approved: Yes (First approved January 8, 2010)
Brand name: Actemra
Generic name: tocilizumab
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Rheumatoid Arthritis, Giant Cell Arteritis, Systemic Sclerosis-Associated Interstitial Lung Disease, Juvenile Idiopathic Arthritis, Cytokine Release Syndrome, COVID-19
Actemra (tocilizumab) is a humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody for the treatment of rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome, and COVID-19.
- Actemra is indicated for the treatment of:
- Rheumatoid Arthritis (RA) - Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
- Giant Cell Arteritis (GCA) - Adult patients with giant cell arteritis.
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
- Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.
- Systemic Juvenile Idiopathic Arthritis (SJIA) - Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
- Cytokine Release Syndrome (CRS) - Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome.
- COVID-19 - Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The use of Actemra to treat hospitalized people ages 2 to less than 18 years old is not FDA approved and remains under Emergency Use Authorization (EUA).
Development timeline for Actemra
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
